Early observations and pilot data that first suggested a new direction
Transurethral resection of the prostate (TURP) had been the gold standard surgical treatment for benign prostatic hyperplasia (BPH) since the 1930s, providing reliable symptom relief and improved urinary flow. However, TURP carried a 2-5% risk of significant complications including TUR syndrome (dilutional hyponatremia from glycine irrigation), bleeding requiring transfusion, retrograde ejaculation (75-90%), and a 1-2% risk of urinary incontinence. For larger prostates (>80-100g), open simple prostatectomy was required, carrying even greater morbidity. The limitations of TURP—particularly its complication profile and inability to treat large prostates efficiently—created demand for safer alternatives that could match TURP's durable efficacy.
Landmark RCTs and pivotal trials that established the evidence base
Holmium laser enucleation of the prostate (HoLEP) emerged as the first technique to challenge TURP's dominance across all prostate sizes. Multiple RCTs demonstrated that HoLEP provided equivalent or superior symptom improvement and flow rates compared to TURP, with significantly less bleeding, shorter catheterization time, and shorter hospital stay. For large prostates (>100g), HoLEP was shown equivalent to open simple prostatectomy with dramatically reduced morbidity. A landmark meta-analysis by Kuntz confirmed HoLEP's superiority for bleeding outcomes while matching TURP for functional results. Critically, HoLEP enucleates the entire adenoma (mimicking open surgery) rather than resecting it piecemeal, providing a more complete treatment with lower retreatment rates at 10 years compared to TURP.
Follow-up studies, subgroup analyses, and real-world validation
A wave of minimally invasive surgical therapies (MISTs) emerged targeting the gap between medical therapy and traditional surgery, specifically for men wanting symptom relief while preserving sexual function. The UroLift prostatic urethral lift was shown in the L.I.F.T. study to improve symptoms with minimal impact on sexual function, though with more modest IPSS improvement than TURP. Rezum water vapor therapy (steam injection) demonstrated durable 4-year symptom improvement in the pivotal trial while preserving ejaculatory function. Most recently, Aquablation (WATER trial, 184 patients; WATER II, 101 patients) demonstrated that robotic waterjet ablation provided TURP-equivalent symptom relief for moderate-to-large prostates with significantly better preservation of ejaculatory function. These MISTs offered an entirely new treatment paradigm: office-based or short-stay procedures preserving sexual function, filling the therapeutic gap between pills and traditional surgery.
Integration into clinical practice guidelines and recommendations
The AUA/SUFU guidelines on BPH management (updated 2024) now include TURP, HoLEP, photoselective vaporization (PVP/GreenLight), UroLift, Rezum, and Aquablation as recommended surgical options, with choice guided by prostate size, anatomy (median lobe), patient priorities (sexual function preservation), and surgeon expertise. HoLEP is recommended for prostates of any size and is increasingly positioned as the new reference standard. NICE guidelines similarly endorse HoLEP, particularly for larger prostates, and include UroLift for prostates <70mL without an obstructing median lobe. The EAU guidelines emphasize that the choice between techniques should be individualized, with transparent discussion of the trade-off between durability (HoLEP/TURP) and sexual function preservation (UroLift/Rezum).
AUA/SUFU Guideline on the Management of BPH
Multiple surgical options recommended based on prostate size and patient goals; HoLEP for any size prostate; UroLift/Rezum for selected patients prioritizing sexual function preservation; TURP remains a standard option
EAU Guidelines on Non-neurogenic Male LUTS including BPO
TURP/bipolar enucleation for prostates <80mL; HoLEP or open/robotic enucleation for >80mL; MISTs (UroLift, Rezum) as alternatives preserving ejaculatory function with counseling about lower durability
Now
Current standard of care and ongoing research directions
BPH surgery has evolved from a one-size-fits-all approach (TURP) to a menu of options tailored to individual patient anatomy, prostate size, and personal priorities. HoLEP is increasingly recognized as the most versatile technique, applicable to all prostate sizes with the lowest retreatment rates, though adoption remains limited by a steep learning curve. MISTs (UroLift, Rezum) have carved a niche for men who prioritize sexual function preservation and accept somewhat less durable symptom relief. Aquablation offers a potential bridge—TURP-equivalent efficacy with better sexual function preservation—though long-term data beyond 5 years are still maturing. Robotic simple prostatectomy has emerged for very large prostates (>150g). The field is moving toward a precision medicine approach where imaging (MRI, transperineal mapping), prostate size, adenoma configuration, and patient-reported outcome priorities guide a shared decision between multiple validated options.
What has replaced TURP as the gold standard for BPH surgery?+
HoLEP (holmium laser enucleation of the prostate) is increasingly considered the new reference standard, as it can treat prostates of any size with equivalent or superior efficacy to TURP, lower bleeding risk, shorter catheterization, and the lowest long-term retreatment rates (2-5% at 10 years vs 10-15% for TURP). However, TURP and bipolar enucleation remain the most widely performed procedures due to HoLEP's steep learning curve (50-100 cases). The choice depends on prostate size, surgeon expertise, and available equipment.
Which BPH procedures preserve ejaculatory function?+
UroLift preserves ejaculatory function in >90% of patients, as it mechanically lifts prostatic lobes without tissue destruction. Rezum preserves ejaculation in approximately 90% of patients. Aquablation preserves ejaculatory function in 80-90% for prostates <80mL. By contrast, TURP causes retrograde ejaculation in 75-90% and HoLEP in 70-80%. For men who prioritize ejaculatory function preservation, UroLift, Rezum, or Aquablation should be discussed, with the caveat that UroLift and Rezum provide somewhat less durable symptom relief.
What are the limitations of UroLift and Rezum?+
UroLift is limited to prostates <80mL without a significantly obstructing median lobe. Five-year data show a retreatment rate of approximately 14%, higher than TURP or HoLEP. Symptom improvement (IPSS reduction of ~8-10 points) is less than TURP/HoLEP (~15-18 points). Rezum has similar prostate size limitations and a retreatment rate of approximately 5-10% at 5 years. Neither procedure provides tissue for histological analysis (cancer detection). Both are best suited for men with moderate symptoms who prioritize sexual function preservation over maximal symptom relief.
What is Aquablation and how does it differ from other BPH treatments?+
Aquablation uses a high-velocity waterjet guided by real-time ultrasound imaging to ablate prostatic tissue with robotic precision. The WATER trial showed it was non-inferior to TURP for symptom improvement while providing significantly better ejaculatory function preservation. WATER II demonstrated efficacy for large prostates (80-150g). Advantages include consistency (robotic execution reduces operator variability), tissue removal for pathology, and suitability for large prostates. Limitations include the need for general anesthesia, specialized equipment, higher cost, and the potential for postoperative bleeding requiring cauterization.
